Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial
- 1 September 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 104 (3) , 443-451
- https://doi.org/10.1097/01.aog.0000137833.43248.79
Abstract
Because small increments in levels of endogenous plasma estradiol are associated with higher postmenopausal bone mineral density, we investigated the safety and effectiveness in preventing bone loss of unopposed, very-low-dose transdermal estradiol for postmenopausal women. This was a randomized, placebo-controlled, double-blind trial with 2-year follow-up at 9 United States clinical centers. The study population comprised 417 postmenopausal women, aged 60-80 years, with intact uterus and bone mineral density z scores of -2.0 or higher, who were randomly assigned to receive either unopposed transdermal estradiol at 0.014 mg/d (n = 208) or placebo (n = 209). All participants received calcium and vitamin D supplementation. Lumbar spine and total hip bone mineral density change was measured by dual-energy X-ray absorptiometry; endometrial hyperplasia incidence was assessed by endometrial biopsy. Median plasma estradiol level in the estradiol group increased from 4.8 pg/mL at baseline to 8.5 pg/mL at 1 year (P <.001 versus baseline) and to 8.6 pg/mL at 2 years (P <.001 versus baseline) and was unchanged in the placebo group. Lumbar spine bone mineral density increased 2.6% in the estradiol group and 0.6% in the placebo group (between-group difference 2.0%, P <.001). Mean total hip bone mineral density increased 0.4% in the estradiol group and decreased 0.8% in the placebo group (between-group difference 1.2%, P <.001). Osteocalcin levels and bone-specific alkaline phosphatase were lower in the estradiol group than the placebo group (P <.001 each). Endometrial hyperplasia developed in 1 woman in the estradiol group but in none of the placebo group (difference in 2-year rates 0.5%, 95% confidence interval 0-7.3%). Postmenopausal treatment with low-dose, unopposed estradiol increased bone mineral density and decreased markers of bone turnover without causing endometrial hyperplasia.Keywords
This publication has 33 references indexed in Scilit:
- Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal WomenJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetateFertility and Sterility, 2001
- Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal womenAmerican Journal of Obstetrics and Gynecology, 2001
- Randomised, Controlled Comparison of Transdermal Estradiol with Oral Conjugated Estrogens for the Relief of Hot FlushesClinical Drug Investigation, 2000
- Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patientsAmerican Journal of Obstetrics and Gynecology, 1999
- Low-Dose Esterified Estrogen TherapyArchives of internal medicine (1960), 1997
- Efficacy and Local Tolerance of a Low-Dose, 7-Day Matrix Estradiol Transdermal System in the Treatment of Menopausal Vasomotor SymptomsObstetrics & Gynecology, 1996
- Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal agesClinical Endocrinology, 1996
- Low-dosage micronized 17ß-estradiol prevents bone loss inpostmenopausal womenAmerican Journal of Obstetrics and Gynecology, 1992